1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T,
Zhong Z, McCue PA, Sang N, Ji JY, et al: Repression of endometrial
tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle.
11:2348–2358. 2012. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Swinnen JV, Brusselmans K and Verhoeven G:
Increased lipogenesis in cancer cells: New players, novel targets.
Curr Opin Clin Nutr Metab Care. 9:358–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Modesitt SC, Hsu JY, Chowbina SR, Lawrence
RT and Hoehn KL: Not all fat is equal: Differential gene expression
and potential therapeutic targets in subcutaneous adipose, visceral
adipose, and endometrium of obese women with and without
endometrial cancer. Int J Gynecol Cancer. 22:732–741. 2012.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang W, Patil S, Chauhan B, Guo S, Powell
DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, et al: FoxO1
regulates multiple metabolic pathways in the liver: Effects on
gluconeogenic, glycolytic, and lipogenic gene expression. J Biol
Chem. 281:10105–10117. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kousteni S: FoxO1, the transcriptional
chief of staff of energy metabolism. Bone. 50:437–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Ho KK, Myatt SS and Lam EW: Many forks in
the path: Cycling with FoxO. Oncogene. 27:2300–2311. 2008.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Chen C, Xu T, Zhou J, Yan Y, Li W, Yu H,
Hu G, Ding X, Chen J and Lu Y: High cytoplasmic FOXO1 and pFOXO1
expression in astrocytomas are associated with worse surgical
outcome. PLoS One. 8:e692602013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Berry E, Hardt JL, Clardy J, Lurain JR and
Kim JJ: Induction of apoptosis in endometrial cancer cells by
psammaplysene A involves FOXO1. Gynecol Oncol. 112:331–336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Barbato D Lettieri, Aquilano K and Ciriolo
MR: FoxO1 at the nexus between fat catabolism and longevity
pathways. Biochim Biophys Acta. 1555–1560. 2014. View Article : Google Scholar
|
13
|
Pavlidou A and Vlahos NF: Molecular
alterations of PI3K/Akt/mTOR pathway: A therapeutic target in
endometrial cancer. Scientific World Journal. 709–736. 2014.
|
14
|
Ward EC, Hoekstra AV, Blok LJ,
Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC and
Kim JJ: The regulation and function of the forkhead transcription
factor, Forkhead box O1, is dependent on the progesterone receptor
in endometrial carcinoma. Endocrinology. 149:1942–1950. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Goto T, Takano M, Albergaria A, Briese J,
Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M,
et al: Mechanism and functional consequences of loss of FOXO1
expression in endometrioid endometrial cancer cells. Oncogene.
27:9–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen G, Liang G, Ou J, Goldstein JL and
Brown MS: Central role for liver X receptor in insulin-mediated
activation of Srebp-1c transcription and stimulation of fatty acid
synthesis in liver. Proc Natl Acad Sci USA. 101:11245–11250. 2004.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Heemers H, Maes B, Foufelle F, Heyns W,
Verhoeven G and Swinnen JV: Androgens stimulate lipogenic gene
expression in prostate cancer cells by activation of the sterol
regulatory element-binding protein cleavage activating
protein/sterol regulatory element-binding protein pathway. Mol
Endocrinol. 15:1817–1828. 2001. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yang Y, Morin PJ, Han WF, Chen T, Bornman
DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase
expression in breast cancer by sterol regulatory element binding
protein-1c. Exp Cell Res. 282:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sun Y, He W, Luo M, Zhou Y, Chang G, Ren
W, Wu K, Li X, Shen J, Zhao X and Hu Y: SREBP1 regulates
tumorigenesis and prognosis of pancreatic cancer through targeting
lipid metabolism. Tumour Biol. 36:4133–4141. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Xiao E and Graves DT: Impact of diabetes
on the protective role of FOXO1 in wound healing. J Dent Res.
94:1025–1026. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wang J, Yang H, Li W, Xu H, Yang X and Gan
L: Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug
resistance in ovarian cancer cells. Biochim Biophys Acta.
1852:395–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhao Y, Tindall DJ and Huang H: Modulation
of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Int J Biol Sci. 10:614–619. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Yu JJ, Wu YX, Zhao FJ and Xia SJ: miR-96
promotes cell proliferation and clonogenicity by down-regulating of
FOXO1 in prostate cancer cells. Med Oncol. 31:9102014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhao JG, Ren KM and Tang J: Zinc finger
protein ZBTB20 promotes cell proliferation in non-small cell lung
cancer through repression of FoxO1. FEBS Lett. 588:4536–4542. 2014.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Yu F, Jin L, Yang G, Ji L, Wang F and Lu
Z: Post-transcriptional repression of FOXO1 by QKI results in low
levels of FOXO1 expression in breast cancer cells. Oncol. Rep.
31:1459–1465. 2014.PubMed/NCBI
|
26
|
Yang J, Li T, Gao C, Lv X, Liu K, Song H,
Xing Y and Xi T: FOXO1 3′UTR functions as a ceRNA in repressing the
metastases of breast cancer cells via regulating miRNA activity.
FEBS Lett. 588:3218–3224. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X
and Song L: Acylglycerol kinase promotes cell proliferation and
tumorigenicity in breast cancer via suppression of the FOXO1
transcription factor. Mol Cancer. 13:1062014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Yu DA, Yoon J, Ko YS, Park J, Kim SY, Kim
MA, Kim JH, Jung J, Cheon Y, Lee HS, et al: Forkhead transcription
factor FOXO1 inhibits nuclear factor-κB in gastric cancer. APMIS.
122:848–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Myatt SS, Wang J, Monteiro LJ, Christian
M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW:
Definition of microRNAs that repress expression of the tumor
suppressor gene FOXO1 in endometrial cancer. Cancer Res.
70:367–377. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Korani M, Fallah S, Tehranian A,
Nourbakhsh M, Samadikuchaksaraei A, Pour MS and Maleki J: The
evaluation of the FOXO1, KLF9 and YT521 genes expression in human
endometrial cancer. Clin Lab. 59:483–489. 2013.PubMed/NCBI
|
31
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers, and the implications for
pathogenesis, classification and targeted therapies. Cancer
Control. 16:8–13. 2009.PubMed/NCBI
|
32
|
Ali IU: Gatekeeper for endometrium: The
PTEN tumor suppressor gene. J Natl Cancer Inst. 92:861–863. 2000.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: The PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Mutter GL, Lin MC, Fitzgerald JT, Kum JB,
Baak JP, Lees JA, Weng LP and Eng C: Altered PTEN expression as a
diagnostic marker for the earliest endometrial precancers. J Natl
Cancer Inst. 92:924–930. 2000. View Article : Google Scholar : PubMed/NCBI
|
35
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View Article : Google Scholar : PubMed/NCBI
|
36
|
Modur V, Nagarajan R, Evers BM and
Milbrandt J: FOXO proteins regulate tumor necrosis factor-related
apoptosis inducing ligand expression. Implications for PTEN
mutation in prostate cancer. J Biol Chem. 277:47928–47937. 2002.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Schmandt RE, Iglesias DA, Co NN and Lu KH:
Understanding obesity and endometrial cancer risk: Opportunities
for prevention. Am J Obstet Gynecol. 205:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
38
|
Renehan AG, Tyson M, Egger M, Heller RF
and Zwahlen M: Body-mass index and incidence of cancer: A
systematic review and meta-analysis of prospective observational
studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
39
|
Shimano H: Sterol regulatory
element-binding proteins (SREBPs): Transcriptional regulators of
lipid synthetic genes. Prog Lipid Res. 40:439–452. 2001. View Article : Google Scholar : PubMed/NCBI
|
40
|
Horton JD and Shimomura I: Sterol
regulatory element-binding proteins: Activators of cholesterol and
fatty acid biosynthesis. Curr Opin Lipidol. 10:143–150. 1999.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Schønberg SA, Lundemo AG, Fladvad T,
Holmgren K, Bremseth H, Nilsen A, Gederaas O, Tvedt KE, Egeberg KW
and Krokan HE: Closely related colon cancer cell lines display
different sensitivity to polyunsaturated fatty acids, accumulate
different lipid classes and downregulate sterol regulatory
element-binding protein 1. FEBS J. 273:2749–2765. 2006. View Article : Google Scholar : PubMed/NCBI
|
42
|
Lin L, Zheng X, Qiu C, Dongol S, Lv Q,
Jiang J, Kong B and Wang C: SIRT1 promotes endometrial tumor growth
by targeting SREBP1 and lipogenesis. Oncol Rep. 32:2831–2835.
2014.PubMed/NCBI
|
43
|
Deng X, Zhang W, O-Sullivan I, Williams
JB, Dong Q, Park EA, Raghow R, Unterman TG and Elam MB: FoxO1
inhibits sterol regulatory element-binding protein-1c (SREBP-1c)
gene expression via transcription factors Sp1 and SREBP-1c. J Biol
Chem. 287:20132–20143. 2012. View Article : Google Scholar : PubMed/NCBI
|